Category Archives: Drug Development

One of the key challenges for bioinformaticians in this age is extracting meaningful findings from abstracts and full text articles. Text mining solutions can only take it so far, and previous comparative studies have shown that Amazon Mechanical Turk solutions and … Continue reading →

Part of what makes user group meetings so interesting is getting the opportunity to peek behind the curtains and see someone else’s operation. In last night’s, KNIME user group meeting, Brock Luty of Dart NeuroScience gave an interesting perspective on … Continue reading →

One of the things that I’m always curious about, is the effect of a sequence variation on the conformation of a target. Recently I wrote about ClinVar and SwissVar, two tools for examining variants and their associations with disease. Since … Continue reading →

The intertubes have been abuzz lately with the news of Merrimack’s results from their Phase III trial of a new triplet therapy for pancreatic cancer. The triplet combines older standard of care drugs like 5FU and leucovorin with their new … Continue reading →

This week Brock Luty of Dart Neuroscience hosted the first San Diego KNIME User Group meeting. Michael Berthold, one of the founders of KNIME, came down from San Francisco to deliver a briefing Mark Donnelly of XIFIN demonstrated how a … Continue reading →

I’m a voracious reader of mysteries in my spare time. And some juncture in every story, as the detective finds himself staring at the corpse, they ask the inevitable question “Cui Bono — who benefits?” Oddly enough, this is a … Continue reading →